This research hub brings together information about the science of Hurler syndrome, ongoing areas of investigation and how families, adults and professionals can engage with research in a safe, informed way.
The information on this page is educational and does not promote or recommend any specific investigational treatment. Always discuss individual decisions with your own medical team.
Understanding today to improve tomorrow
Hurler syndrome affects multiple organs and systems and remains a serious condition even with HSCT, enzyme replacement therapy and modern supportive care. Research is important because it can:
- Clarify how IDUA deficiency and glycosaminoglycan (GAG) storage damage different tissues
- Improve diagnosis and newborn screening strategies
- Identify better markers of disease severity and progression
- Refine current treatments and improve timing, dosing and supportive care
- Support development of new approaches, such as gene therapy, gene editing or advanced delivery systems
- Provide real world data on long term outcomes, quality of life and unmet needs
Families, adults and clinicians all benefit from high quality, transparent research.
From genes and cells to everyday life
Here are the major research themes shaping our understanding and treatment of Hurler syndrome:
Basic and translational science
Research that explores:
- IDUA gene variants and how they influence enzyme activity
- Lysosomal biology and GAG storage in different cell types
- Animal and cellular models used to test new therapies
- Drug delivery technologies that aim to reach brain, bone and cartilage more effectively
Clinical outcomes and natural history
Studies that follow children and adults over time to:
- Describe how different organs are affected
- Understand how early HSCT and ERT change survival and quality of life
- Identify which complications remain common despite treatment
- Provide data that can inform guidelines and trial design
Imaging, biomarkers and monitoring
Work that aims to improve assessment of disease and treatment response, for example:
- Advanced MRI, CT and echocardiography for heart, brain and skeleton
- Laboratory markers of GAG storage and downstream damage
- Neurocognitive and functional assessments
New and emerging therapies
Research investigating:
- Modified transplant or enzyme replacement strategies
- Gene therapy or gene editing approaches
- Novel vectors and delivery systems designed to reach hard-to-treat tissues
- Combination approaches that may complement existing standards of care
These are investigational programmes and participation is always voluntary.
Long term data that shape future care
Registries and long term follow up studies collect structured information about people with Hurler syndrome. They help clinicians and researchers to:
- Map patterns of disease progression over years and decades
- Compare outcomes for different treatments and timing of HSCT or ERT
- Identify risk factors for specific complications
- Understand real world quality of life, education and employment outcomes
For families and adults:
- Taking part usually involves sharing clinical data and sometimes completing questionnaires
- Participation does not change your standard medical care
- You can ask what kind of data is collected, how it is stored and how confidentiality is protected
- Map patterns of disease progression over years and decades
- Compare outcomes for different treatments and timing of HSCT or ERT
- Identify risk factors for specific complications
- Understand real world quality of life, education and employment outcomes
Making sense of scientific papers and news
Research on Hurler syndrome can be complex and sometimes written in highly technical language. When you encounter a paper or news story, consider:
- What type of study is it? (Laboratory model, animal study, small early trial, larger trial, registry analysis)
- How many participants were involved and how long were they followed?
- What outcomes were measured (for example survival, organ function, quality of life)?
- Were there side effects or complications?
- Is the treatment described being used in routine care yet, or is it still experimental?
It can be helpful to:
- Bring research articles or summaries to clinic and ask your team to help interpret them
- Be cautious about headlines that promise a ‘cure’ without details
- Remember that individual responses vary, and no single study tells the whole story
For families and adults: engaging with research
Questions you might want to ask
If you are invited to take part in a study or trial, or are considering asking about one, you might ask:
- 1. What is the purpose of this study?
- 2. What does taking part involve, in practical terms (visits, tests, time, travel)?
- 3. What are the possible benefits and possible risks for me or my child?
- 4. How does this compare to standard care?
- 5. What happens if we decide to stop taking part?
- 6. How will our data be protected and who will have access to it?
- 7. Will we find out the overall results of the study afterwards?
You can take time to decide and may wish to discuss with other family members or trusted professionals.
For researchers and clinicians: principles of good research practice
Respectful, collaborative science in a rare disease
Research in Hurler syndrome should:
- Be based on clear scientific rationale and realistic objectives
- Respect the time, energy and emotional burden on families and adults
- Include appropriate ethical approvals and robust consent processes
- Ensure data protection and confidentiality
- Involve families, adults and patient organisations in designing priorities and outcomes where possible
- Share results transparently, including negative or inconclusive findings
Collaborative work between centres is especially important in rare conditions, where numbers at each site are small.
Key themes from published work
This section provides key resources for understanding published research on Hurler syndrome:
Lay Summaries
Accessible summaries of important scientific publications about Hurler syndrome to help families and patients understand key research findings.
Guidelines & Reviews
Links and references to consensus guidelines and comprehensive review articles that shape current understanding and clinical practice.
Research Highlights
Brief explanations of findings from longitudinal studies examining heart, brain and skeletal outcomes in MPS I H.
Glossary
Helpful definitions of technical and scientific terms that appear in research papers and medical literature.
Further detail from the source pages
Further detail6 sections
When taking part in research, children, adults and families should be reassured that:
- Studies undergo review by ethics committees or institutional review boards
- Data are stored securely, with identifiers removed or coded where possible
- Published results do not identify individuals
- You can ask how long data will be stored and for what purposes
- You have the right to ask questions at any time before, during and after participation
- If you have concerns about a study, you can raise them with the research team, your usual clinical team or appropriate oversight bodies
Key points about the research hub
- Research in Hurler syndrome spans basic science, clinical outcomes, registries, imaging, biomarkers and new treatments.
- Registries and long term studies help describe the natural history of MPS I H and the impact of HSCT, ERT and supportive care.
- Clinical trials offer access to investigational therapies but always involve potential risks as well as possible benefits.
- Families and adults should feel empowered to ask questions, take time to decide and use their specialist team to interpret research.
- Researchers and clinicians have a responsibility to design ethical, collaborative studies and to share results clearly and transparently.
About Hurler syndrome
Scientific and clinical background
Natural history and outcomes
Disease course and impact of treatment
Treatments and care
Current standard therapies and supportive care
Living with Hurler syndrome
Everyday life, school, work and planning ahead
Further detail — part 22 sections
Support and community
Patient organisations, support groups and practical help
Glossary
Definitions of scientific and clinical terms
Home > For researchers
More: For researchers6 sections
Research in Hurler syndrome (MPS I-H)
This area of hurlersyndrome.org is dedicated to researchers and research-focused clinicians working on Hurler syndrome, the severe form of MPS I. It brings together scientific foundations, translational and preclinical work, clinical research priorities, registry-based evidence and opportunities for collaboration.
Whether your work focuses on lysosomal biology, gene and cell therapy, clinical trials, epidemiology or health services research, this page directs you to MPS I-H specific resources and content.
For researchers and research-focused clinicians only. Content does not replace formal protocols, regulatory guidance or ethics approval.
Who this page is for
This section is intended for professionals involved in research across the MPS I-H spectrum, including:
- Basic scientists studying lysosomal function, GAG metabolism and neurodegeneration
- Translational researchers developing gene therapy vectors and systemic delivery platforms
- Clinical researchers in metabolic medicine, transplantation, paediatrics, neurology, cardiology and orthopaedics
- Data scientists and epidemiologists analysing registry and real-world datasets
- Industry partners evaluating MPS I-H as a model indication for emerging platforms
Scientific and clinical questions
Hurler syndrome raises critical questions spanning lysosomal biology, CNS disease, skeletal pathology, transplant medicine and systemic gene delivery. Core research themes include:
Gene therapy and advanced therapeutic approaches
MPS I-H is a strong candidate for systemic gene therapy due to its well-defined biochemical defect, severe untreated course and established HSCT and ERT standards that provide a clear clinical baseline.
Rationale for gene therapy
- Limits of HSCT and ERT in CNS and skeletal disease
- Need for durable, body-wide enzyme delivery
Vector design and mechanism
- Lentiviral construct and promoter selection
- IDUA transgene and tissue targeting strategy